Tesamorelin

Tesamorelin (also known as Egrifta) is a prominently researched experimental compound classified strictly within the GHRH Analog framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it stimulates GH for fat metabolism. Binds to GHRH receptors on the pituitary gland to stimulate natural growth hormone production, specifically targeting visceral adipose tissue. with a documented biological half-life of roughly 0.43 hours, In preclinical investigative trials and independent academic studies, researchers utilizing Tesamorelin have documented significant, quantifiable biological outcomes, primarily focusing on visceral fat reduction, body recomposition. Typical research protocols investigate administering 1000 to 1000mcg via subq pathways 7x/week. However, it is critically important to understand that while Tesamorelin demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.